A5005090790- Phytochemical Studies and Bioactivities
- Chromatography in Natural Products
- Cancer Treatment and Pharmacology
- Head and Neck Cancer Studies
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Natural product bioactivities and synthesis
- Colorectal Cancer Treatments and Studies
- Flavonoids in Medical Research
- Colorectal and Anal Carcinomas
- Thyroid Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Nutrition and Health in Aging
- Immune Cell Function and Interaction
- Oral health in cancer treatment
- Lymphoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Glycosylation and Glycoproteins Research
- Cancer Research and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Lung Cancer Research Studies
- Vascular Tumors and Angiosarcomas
- Inflammatory Biomarkers in Disease Prognosis
Japanese Foundation For Cancer Research
2013-2025
The Cancer Institute Hospital
2004-2025
Memorial Sloan Kettering Cancer Center
2024
University of Tokyo Hospital
2017-2024
Tokyo Medical and Dental University
2024
The University of Tokyo
2016-2024
Cancer Institute (WIA)
2013
Asahikawa Medical College Hospital
2006
Abstract Eyelid squamous cell carcinoma is a major type of rare eyelid cancer, together with basal and sebaceous gland carcinoma. It painless disease that progresses slowly often detected by the appearance nodules or plaques. Risk factors include exposure to ultraviolet light, fair skin, radiation human papillomavirus infection. The standard treatment surgical removal, in cases orbital invasion, content removal required. If sentinel node biopsy reveals high risk lymph metastasis, adjuvant...
Neuroendocrine carcinoma (NEC) of the head and neck is a rare type malignancy, accounting for only 0.3% all cancers, its clinicopathological genomic features have not been fully characterized. We conducted retrospective analysis 27 patients with poorly differentiated NEC seen at our institution over period 15 years. Patient characteristics, adopted therapies, clinical outcomes were reviewed based on medical records. Pathological targeted sequencing 523 cancer-related genes performed using...
Abstract Background Platinum and anti-PD-1 antibodies are the front-line systemic therapy for recurrent or metastatic head neck squamous cell carcinoma (RM-HNSCC). However, limited data available on clinical outcomes appropriate regimens patients with RM-HNSCC following treatment failure these agents. Patients methods We retrospectively analyzed of from 10 Japanese institutions in whom platinum nivolumab failed. Results Of 480 included study, 236 were treated best supportive care had a...
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR-DTC). Little is known whether NLR can a tumor marker RR-DTC patients treated lenvatinib. Patients and Methods: We retrospectively analyzed was calculated at 4 points before during lenvatinib treatment. Results: The median value increased the start of treatment, compared 6 months prior initiation overall...
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers ATC treated lenvatinib lacking. The aim this study was to explore whether neutrophil-to-lymphocyte ratio (NLR) can be a marker lenvatinib. Patients and Methods: We retrospectively analyzed prognostic significance NLR in 13 Results: disease control rate better lower (<8; 89%) than higher (≥8; 25%) (p=0.05). Median progression-free survival overall were longer (4.0...
Abstract Background In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation eribulin) in Japanese patients with advanced solid tumors. Methods This study enrolled adult to receive for treatment Treatment 2.0 mg/m 2 every 3 weeks (previously determined maximum tolerated dose) was tested adenoid cystic carcinoma, gastric cancer, esophageal or small lung cell cancer expansion part study. Secondary endpoints included safety, objective response...
Abstract Background Since homologous recombination deficiency (HRD) is relatively uncommon in pancreatic cancer (PC), its impact on time-to-treatment failure (TTF) among patients undergoing systemic chemotherapy for unresectable and recurrent PC remains uncertain. Methods Among with enrolled the Center Cancer Genomics Advanced Therapeutics (C-CAT) database by July 2023, a total of 1394 who underwent first-line either gemcitabine plus nab-paclitaxel (GnP) or FOLFIRINOX (FFX) received...
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC), nivolumab conferred a survival benefit to patients. However, best treatment sequence of chemotherapy anti-PD-1/PD-L1 therapy in these cancers is unclear. Patients Methods: This was an observational study using data collected prospectively from 97 HNC patients treated with at our institutions. Twenty-two who received paclitaxel-based before (pre-PTX, n=12) after (post-PTX, n=10) were evaluated. Results: The...
Abstract Purpose Docetaxel + cisplatin 5-fluorouracil (DCF) therapy, a frequently prescribed regimen for esophageal cancer, is associated with high risk of febrile neutropenia (FN). This study investigated whether low skeletal muscle mass index (SMI) an independent factor FN. Methods retrospective, observational the SMI patients cancer who received DCF therapy between March 2018 and July 2020. Based on Asian sarcopenia criteria, were divided into two groups: (SMI < 7.0 5.7 kg/m 2 males...
Cetuximab and bevacizumab reportedly improve the survival of patients with metastatic colorectal cancer (mCRC), but their most effective sequence administration is unknown. The aim this study was to compare mCRC treated cetuximab after failure that without previous therapy.In total, 190 323 from March 2006 July 2013 were enrolled in our hospital for retrospective study. Forty-seven cetuximab-based second-line therapy, 21 whom had received prior bevacizumab; 143 third-line 109 bevacizumab....
Abstract Objectives A better understanding of antitumor immunity will help predict the prognosis gastric cancer patients and tailor appropriate therapies in each patient. Therefore, we propose a novel immunological classification cancer. Methods We performed whole‐exome sequencing (WES), RNA‐Seq flow cytometry 29 who received surgery. The TCGA data set 323 45 pembrolizumab (Kim et al . Nat Med 2018; 24 : 1449–1458) were also analysed. Results Immunogram analysis cancer–immunity interaction...
In the CheckMate-141 trial, nivolumab conferred a survival benefit in patients with recurrent or metastatic refractory squamous cell carcinoma (SCC) head and neck cancer (HNC). Here, we examined efficacy of histological subtypes primary sites HNC not included trial.This was retrospective analysis data collected prospectively from 97 who were treated for at our institution. The assigned to three groups based on site: 1) oral cavity, pharynx, larynx, which (n = 68), 2) nasopharynx (excluded...
There have been few reports on the evaluation of cancer cachexia based skeletal muscle mass index (SMI) in patients with head and neck cancer.One hundred ninety-two were enrolled. In definitive adjuvant chemoradiotherapy settings, clinical outcomes compared between non-cachexia patients.Forty diagnosed (20.8%). setting, overall survival (OS) was significantly shorter group (3-year OS: 50.0% vs 88.5%; p < 0.01), multivariate analysis identified UICC stage IV, baseline albumin <4 as poor...
Lenvatinib is a standard therapy for radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, because of the high incidence adverse events resulting from this treatment, it not easy to maintain dose intensity lenvatinib, especially in Japanese patients. Although prognostic impact lenvatinib interruption has been reported, target optimize survival benefits remains unknown. We therefore propose during first 8 weeks treatment. retrospectively analyzed 42 RR-DTC patients who were...
Although high-dose cisplatin is the standard regimen of concurrent chemoradiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (HNSCC), varying levels patient tolerance towards have been reported, predictive factors remain to be elucidated. The present study retrospectively reviewed newly diagnosed HNSCC patients who received CCRT. Cisplatin (80 mg/m2) was administered every 3 weeks. proportion cisplatin-tolerant (cumulative dose, ≥200 determined, were analyzed in a...
Pazopanib with trabectedin and eribulin is widely used to treat soft-tissue sarcoma (STS). We have shown that baseline neutrophil-to-lymphocyte ratio (NLR) may predict the efficacy patient prognosis of eribulin. Changes in NLR, but not can trabectedin. However, prognostic factors pazopanib for STS been identified. present a retrospective analysis 141 patients treated recurrent or metastatic non-round cell STS. Univariate multivariate analyses were performed determine predictive durable...
Abstract Purpose: In the dose-expansion part of this open-label, phase I study, we explored efficacy and safety E7389-LF (liposomal formulation eribulin) in Japanese patients with advanced gastric cancer. Patients Methods: cancer who had been previously treated ≥2 lines chemotherapy received 2.0 mg/m2 every 3 weeks (the determined maximum tolerated dose, primary objective Study 114). Secondary objectives included response rate (ORR), progression-free survival (PFS), safety; exploratory...
We investigated the tumor immune response in gastric cancer patients receiving third-line nivolumab monotherapy to identify immune-related biomarkers for better patient selection. Nineteen (10 males, median age 67 years) who received as a third- or later-line therapy were enrolled. analyzed durable clinical benefit (DCB) and non-DCB patients. Pre-treatment early-on-treatment transcriptomes examined, gene expression profiles, immunograms, T cell receptor (TCR) repertoire analyzed. DCB was...
Proteinuria has been described as a major on-target adverse event of lenvatinib, although its long-term impact on renal function and clinical outcomes remains unclear. We conducted retrospective observational study to assess prognosis in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) receiving lenvatinib. Overall, 70 RR-DTC treated lenvatinib were enrolled. When proteinuria was observed, the dose schedule adjusted achieve urine protein-to-creatinine ratio (UPCR)...
Immune checkpoint inhibitor therapy is effective only for a subset of patients with gastric cancer. Impaired neoantigen presentation caused by deficiency human leukocyte antigen class I (HLA-I) has been reported as common mechanism immune evasion which associated resistance to blockade. To elucidate the significance HLA-I in cancer special focus on microsatellite instable (MSI) and Epstein-Barr virus (EBV)-positive tumors, we examined expression tumor cells correlated results...
Background/Aim: Lenvatinib is standard therapy for radioiodine-refractory differentiated thyroid cancer (RR-DTC), although the optimal timing starting treatment still controversial. The aim of this study was to evaluate prognostic impact baseline tumour size (BTS) in patients with RR-DTC treated lenvatinib. Patients and Methods: Fifty-one who had at least one measurable lesion lenvatinib were retrospectively analysed. BTS defined as sum longest dimensions all target lesions. Results: Median...